|
8 de abril de 2009, 18h40
|
|
VIVALIS: PARTICIPACIÓN EN EL SMALLCAP EVENT LOS 27 Y 28 DE ABRIL DE 2009 EN PARÍS
|
Nantes (Francia) - 8 de abril de 2009
VIVALIS (NYSE Euronext París: VLS), compañía biofarmacéutica que proporciona a la industria farmacéutica innovadoras soluciones basadas en células para la producción de vacunas y proteínas y que desarrolla medicamentos para prevenir y tratar enfermedades víricas, participará en el Smallcap Event que se celebrará los días 27 y 28 de abril de 2009 en París (Hotel Pullman Tour Eiffel, 18 avenue de Suffren).
VIVALIS presentará sus avances tecnológicos y comerciales del 2008, los resultados financieros, incluso los ingresos netos notablemente positivos durante el citado año, así como sus perspectivas estratégicas.
VIVALIS' presence at this forum reflects its commitment to develop strong relations with investors and raise its visibility within the financial community. The Smallcap Event will also provide an opportunity for fund managers to meet Franck Grimaud, VIVALIS' CEO, to learn more about the company, its market and strategic outlook.
*******************
Financial press release:
29 April 2009, after NYSE Euronext market closing: 2009 first-quarter sales
About VIVALIS (www.vivalis.com)
VIVALIS (NYSE - Euronext (Paris: NL0000290641 - noticias) : VLS) is a biopharmaceutical company that provides the pharmaceutical industry innovative cell-based solutions for the manufacture of vaccines and proteins, and develops drugs to prevent and treat viral diseases. VIVALIS' know-how and proprietary technologies are commercially exploited in three main areas:
1. The development and manufacturing of vaccines. VIVALIS offers research and commercial licenses for its EB66® cell line, derived from duck embryonic stem cells, to pharmaceutical and biotechnology companies for the production of viral vaccines. VIVALIS receives upfront fees, milestone payments and royalties on its licensees' net sales.
2. The development of production systems for recombinant proteins and monoclonal antibodies. VIVALIS licenses to pharmaceutical and biotechnology companies its EB66® cell line for the production of recombinant proteins. VIVALIS receives upfront fees, milestone payments and royalties on its licensees' net sales.
3. The construction of a portfolio of proprietary products in the area of vaccines and anti-viral molecules (Hepatitis C).
Based in Nantes (France), VIVALIS was created in 1999 by Group Grimaud (1,450 employees), the n°2 group worldwide in animal genetic breeding. VIVALIS has established more than 30 partnerships with worldwide leaders in the sector. VIVALIS is a member of the French Atlantic Biotherapies cluster.
| VIVALIS | | Listed on Euronext Paris - Compartment C of NYSE Euronext | | Reuters: VLS.PA - Bloomberg: VLS FP | | Member of NYSE Euronext's Next Biotech index |
Investor Relations:
VIVALIS
Franck Grimaud, CEO
Email: investors@vivalis.com
NewCap
Financial communication Agency
Steve Grobet / Emmanuel Huynh
Tel.: +33 (0) 1 44 71 94 91
Email: vivalis@newcap.fr
Copyright Hugin
Este anuncio fue transmitido por Hugin. El emisor es el único responsable del contenido.
[CN#151624]
|
|
|
